LOGIN  |  REGISTER
Recursion
Compass Therapeutics

PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference

September 21, 2023 | Last Trade: US$0.60 0.005 0.84

NEW YORK, Sept. 21, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or "Lucid Diagnostics"), a commercial-stage cancer prevention diagnostics company, today announced their participation in the 2023 Cantor Fitzgerald Global Healthcare Conference in New York City.  

Lishan Aklog, M.D., PAVmed and Lucid's Chairman & Chief Executive Officer, and Dennis McGrath, PAVmed's President and Chief Financial Officer and Lucid's Chief Financial Officer, will participate in a panel presentation on Wednesday, September 27, 2023, at 8:00 a.m. EDT.

About PAVmed and its Subsidiaries

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other majority-owned subsidiary, Veris Health Inc., is a private, commercial-stage digital health company focused on enhancing cancer care through remote monitoring and virtual care using the Veris Cancer Care Platform. Veris is concurrently developing a fully implantable, intelligent, physiologic monitor for attachment and coimplantation with a vascular access port that will further enhance the clinical and commercial value of the platform by providing physiologic data to the care providers, independent of patient compliance.

For more and for more information about PAVmed, please visit pavmed.com.

For more information about Lucid Diagnostics, please visit luciddx.com.

For more information about Veris Health, please visit verishealth.com

Recursion

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page